Journal article
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
The Lancet (British edition), Vol.343(8911), pp.1460-1463
1994
DOI: 10.1016/S0140-6736(94)92581-X
PMID: 7911177
Abstract
Summary
Immunotherapy of chronic viral diseases with vaccines is an important but unproven concept. We investigated the effect of a vaccine containing recombinant glycoprotein D (gD2) of herpes simplex virus type 2 (HSV-2) on the frequency of symptomatic outbreaks in patients with genital herpes. 98 patients with documented genital herpes who reported 4-14 recurrences per year were enrolled in a double-blind, placebo-controlled trial. Subjects received injections of either 100 μg gD2 in alum or alum alone (placebo) at 0 and 2 months, and recurrences were documented for 1 year. The vaccine was well tolerated. gD2 recipients reported fewer recurrences per month than placebo recipients (mean 0·42 [SE 0·05] vs 0·55 [0·05]; p=0·055), had fewer virologically confirmed recurrences per month (0·18 [0·03] vs 0·28 [0·03]; p=0·019), and had a lower median number of recurrences for the study year (4 [range 0-17] vs 6 [0-15]; p=0·039). Neither genital recurrence nor the placebo vaccine had any discernible effect on HSV-2-specific antibody responses, but gD2 vaccine boosted neutralising antibodies to HSV-2 fourfold and gD2-specific titres sevenfold over baseline levels.
These results inspire optimism about the potential use of vaccine for the treatment of chronic, recurring viral diseases.
Details
- Title: Subtitle
- Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
- Creators
- Stephen E Straus - Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N-228, Bethesda, Maryland 20892, United StatesLawrence Corey - Division of Virology, Departments of Laboratory Medicine and Medicine, University of Washington, Seattle, Washington, United StatesRae Lyn Burke - Biocine Company, Emeryville, California, U.S.ABarbara Savarese - Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N-228, Bethesda, Maryland 20892, United StatesGail Barnum - Division of Virology, Departments of Laboratory Medicine and Medicine, University of Washington, Seattle, Washington, United StatesPhillip R Krause - National Institute of Allergy and Infectious DiseasesRhonda G Kost - Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N-228, Bethesda, Maryland 20892, United StatesJeffery L Meier - Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N-228, Bethesda, Maryland 20892, United StatesRose Sekulovich - Biocine Company, Emeryville, California, U.S.ASuzanne F Adair - Biocine Company, Emeryville, California, U.S.ACornelia L Dekker - Biocine Company, Emeryville, California, U.S.A
- Resource Type
- Journal article
- Publication Details
- The Lancet (British edition), Vol.343(8911), pp.1460-1463
- Publisher
- Elsevier Ltd
- DOI
- 10.1016/S0140-6736(94)92581-X
- PMID
- 7911177
- ISSN
- 0140-6736
- eISSN
- 1474-547X
- Language
- English
- Date published
- 1994
- Academic Unit
- Infectious Diseases; Epidemiology; Internal Medicine
- Record Identifier
- 9984094721002771
Metrics
8 Record Views